Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease

Cardiovascular Diseases Clinical Trial

Official title:

The Impact of Dual Bronchodilation on Respiratory and Cardiovascular Systems in Patients With Newly Diagnosed Moderate-to-severe Chronic Obstructive Pulmonary Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06072690
• Other study ID #: COPDCVS1
• Status: Recruiting
• Start date: April 15, 2021
• Est. completion date: August 31, 2026

Study information

• Verified date: October 2023
• Source: Lithuanian University of Health Sciences
• Contact: Skaidrius Miliauskas, PhD, Prof.
• Phone: +37037326269
• Email: skaidrius.miliauskas[@]lsmu.lt
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) is a major cause of disability and death worldwide. People with COPD often have cardiovascular diseases (CVDs) that are associated with increased risk for hospitalization and prolonged stay as well as all-cause and CVD-related mortality. Nevertheless, CVDs in patients with COPD are tend to be underestimated in clinical practice. Mechanisms that define the relation between COPD and cardiovascular morbidity include lung hyperinflation, hypoxia, pulmonary hypertension, systemic inflammation and oxidative stress, exacerbation, shared risk factors and COPD phenotypes. Recently, some authors have announced that COPD treatment with dual bronchodilation may not only improve pulmonary function and quality of life, but also have a positive effect on cardiac function in cardiac magnetic resonance imaging (MRI) or two-dimensional cardiac ultrasound for the assessments. The aim of this study is to specify the state of respiratory and cardiovascular systems as well as exercise capacity and quality of life in patients with newly diagnosed moderate-to-severe COPD and to evaluate their changes after short-term treatment with dual bronchodilation. We hypothesize that patients with newly diagnosed COPD and no previous records of cardiac diseases and no apparent signs of heart failure have significantly impaired cardiac autonomic integrity that precedes to increased risk of cardiovascular events. It is believed that cardiac autonomic integrity might significantly improve with dual bronchodilation therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: August 31, 2026
• Est. primary completion date: August 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Aged 40 years and older

• Smoking index of 10 pack-years and more

• Newly diagnosed chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) 30-79 percent of predicted and forced expiratory volume in 1 second to forced vital capacity ratio (FEV1/FVC) less than 70 percent of predicted.

Exclusion Criteria:

• Active lung infection

• Present or previously treated lung cancer

• Alpha-1 antitrypsin deficiency

• Diagnosed interstitial lung disease

• Previously diagnosed asthma

• Diagnosed chronic hypercapnic respiratory failure

• Treatment with systemic glucocorticoids

• Unstable ischaemic heart disease

• Pregnancy

• Present cardiac arrhythmias

• Uncontrolled arterial hypertension

• Dementia and other mental states that determine patient's inability to consent

• Other medical conditions that in the opinion of the investigator disqualify the subject for inclusion

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Chronic Obstructive Pulmonary Disease Moderate
• Chronic Obstructive Pulmonary Disease Severe
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive
• Quality of Life

Locations

Country	Name	City	State
Lithuania	Lithuanian University of Health Sciences	Kaunas

Sponsors (1)

Lead Sponsor	Collaborator
Lithuanian University of Health Sciences

Country where clinical trial is conducted

Lithuania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in exercise capacity at week 12	The effect of dual bronchodilation on exercise capacity (6 minute walk distance test and cardiopulmonary exercise test results) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease	Baseline and week 12
Primary	Change from baseline in Short Form 36 Health Survey Questionnaire at week 12	The effect of dual bronchodilation on quality of life (Short Form 36 Health Survey Questionnaire (SF-36) results) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease	Baseline and week 12
Secondary	Change from baseline in forced expiratory volume in 1 second at week 12	The effect of dual bronchodilation on forced expiratory volume in 1 second (FEV1) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease	Baseline and week 12
Secondary	Change from baseline in forced vital capacity at week 12	The effect of dual bronchodilation on forced vital capacity (FVC) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease	Baseline and week 12
Secondary	Change from baseline in diffusing capacity of the lungs for carbon monoxide at week 12	The effect of dual bronchodilation on diffusing capacity of the lungs for carbon monoxide (DLCO) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease	Baseline and week 12
Secondary	Change from baseline in airway resistance at week 12	The effect of dual bronchodilation on airway resistance (described as specific air resistance (sRaw) and total airway resistance (Raw tot)) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease	Baseline and week 12
Secondary	Change from baseline in residual volume at week 12	The effect of dual bronchodilation on residual volume (RV) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease	Baseline and week 12
Secondary	Change from baseline in residual volume to total lung capacity ratio at week 12	The effect of dual bronchodilation on residual volume to total lung capacity ratio (RV/TLC) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease	Baseline and week 12
Secondary	Change from baseline in forced residual capacity to total lung capacity ratio at week 12	The effect of dual bronchodilation on forced residual capacity to total lung capacity ratio (FRC/TLC) in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease	Baseline and week 12
Secondary	Change from baseline in right ventricle end-systolic volume index at week 12	The effect of dual bronchodilation on right ventricle end-systolic volume index (RVESVi) in patients with newly diagnosed moderate-to-severe COPD	Baseline and week 12
Secondary	Change from baseline in right ventricle end-diastolic volume index at week 12	The effect of dual bronchodilation on right ventricle end-diastolic volume index (RVEDVi) in patients with newly diagnosed moderate-to-severe COPD	Baseline and week 12
Secondary	Change from baseline in on left ventricle end-systolic volume index at week 12	The effect of dual bronchodilation on left ventricle end-systolic volume index (LVESVi) in patients with newly diagnosed moderate-to-severe COPD	Baseline and week 12
Secondary	Change from baseline in left ventricle end-diastolic volume index at week 12	The effect of dual bronchodilation on left ventricle end-diastolic volume index (LVEDVi) in patients with newly diagnosed moderate-to-severe COPD	Baseline and week 12
Secondary	Change from baseline in stroke volume index at week 12	The effect of dual bronchodilation on stroke volume index (SVi) in patients with newly diagnosed moderate-to-severe COPD	Baseline and week 12
Secondary	Change from baseline in right ventricular strains at week 12	The effect of dual bronchodilation on right ventricular strains in patients with newly diagnosed moderate-to-severe COPD	Baseline and week 12
Secondary	Change from baseline in washout rate at week 12	The effect of dual bronchodilation on washout rate (WR) in cardiac sympathetic imaging with meta-iodobenzylguanidine in patients with newly diagnosed moderate-to-severe COPD	Baseline and week 12
Secondary	Change from baseline in heart to mediastinum ratio at week 12	The effect of dual bronchodilation on early and late heart to mediastinum ratio (HMR) in cardiac sympathetic imaging with meta-iodobenzylguanidine in patients with newly diagnosed moderate-to-severe COPD	Baseline and week 12
Secondary	Change from baseline in left ventricle total defect score at week 12	The effect of dual bronchodilation on early and late left ventricle early total defect score (TDS) in cardiac sympathetic imaging with meta-iodobenzylguanidine in patients with newly diagnosed moderate-to-severe COPD	Baseline and week 12